ERBB2 and breast carcinoma: Our experience highlights the importance and potential added value of routine sequencing in patients with HER2-positive breast cancer during the course of treatment with anti-HER2 agents to help define the best maintenance of treatment effect, as this may serve as a potential surrogate marker for treatment response and relapse.